We’re thrilled to announce that Clinical Accelerator is partnering with Angiolutions, a groundbreaking medtech company developing the A³-Shield®, the first-of-its-kind implant designed to stop the progression of abdominal aortic aneurysms (AAA) .

AAAs affect millions worldwide, with no available therapy to halt disease progression. Angiolutions’ innovation is based on pioneering research from Stanford University and represents the first major advance in the AAA field in over 30 years . By blocking harmful aortic pulse wave propagation, A³-Shield® has the potential to protect patients at the early stages of AAA, preventing growth and rupture — and saving lives. Through this collaboration, Clinical Accelerator will support Angiolutions in accelerating their early clinical development program, paving the way toward regulatory approvals and market access in both Europe and the U.S. We look forward to working together to bring this transformative therapy to patients who urgently need new solutions.